MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Apomorphine"

  • MDS Virtual Congress 2020

    Apomorphine as a Diagnostic tool to Identify Levodopa Responsive Atypical Parkinsonism

    M. Faisal, D. Sreenivasa, R. Jayachandran, R. Seetharam, R. Iyer, P. Kukkle (Bengaluru, India)

    Objective: To assess the efficacy of apomorphine in identification of levodopa responsive atypical parkinsonism. Background: Management of atypical parkinsonism is a challenge. Most of these…
  • MDS Virtual Congress 2020

    A Long-Term Safety, Tolerability, and Efficacy Study of Apomorphine Sublingual Film for On-Demand Treatment of “OFF” Episodes in Patients With Parkinson’s Disease: Interim Results

    S. Factor, W. Ondo, S. Isaacson, P. Bhargava, B. Navia (Atlanta, GA, USA)

    Objective: Evaluate the long-term safety (LTS), tolerability, and efficacy of apomorphine sublingual film (APL-130277; APL) for on-demand treatment of “OFF” episodes in patients with Parkinson’s…
  • MDS Virtual Congress 2020

    Reduction of OFF time with apomorphine infusion during hours of pump use: Analysis from a Phase III, open-label study

    S. Isaacson, A. Espay, R. Pahwa, T. Clinch, P. LeWitt (Boca Raton, FL, USA)

    Objective: Evaluate the efficacy of apomorphine (APO) infusion in reducing OFF time during the hours of pump use in PD patients with motor fluctuations inadequately…
  • MDS Virtual Congress 2020

    Apomorphine Sublingual Film for On-Demand Treatment of “OFF” Episodes in Patients With Parkinson’s Disease: Impact on Dyskinesia

    K. Klos, J. Hui, B. Robottom, P. Bhargava, B. Navia (Tulsa, OK, USA)

    Objective: Assess impact of apomorphine sublingual film (APL-130277; APL) on time spent with and functional impact of dyskinesia among patients with Parkinson’s disease (PD) and…
  • MDS Virtual Congress 2020

    A Long-Term Safety, Tolerability, and Efficacy Study of Apomorphine Sublingual Film for On-Demand Treatment of “OFF” Episodes in De Novo vs Rollover Patients With Parkinson’s Disease: Interim Results

    R. Pahwa, S. Fox, C. Singer, P. Bhargava, B. Navia (Kansas City, KS, USA)

    Objective: Evaluate long-term safety (LTS), tolerability, and efficacy of apomorphine sublingual film (APL-130277; APL) for on-demand treatment of “OFF” episodes in de novo (DN) vs…
  • MDS Virtual Congress 2020

    Apomorphine Sublingual Film for On-Demand Treatment of “OFF” Episodes in Patients With Parkinson’s Disease: Effect on MDS-UPDRS Part III Subdomains

    M. Siddiqui, V. Evidente, P. Bhargava, B. Navia, E. Pappert (Winston-Salem, NC, USA)

    Objective: Evaluate effect of apomorphine sublingual film (APL-130277; APL) as an on-demand treatment of “OFF” episodes in patients with Parkinson’s disease (PD) on MDS-UPDRS Part…
  • MDS Virtual Congress 2020

    Dose Optimization of Apomorphine Sublingual Film for On-Demand Treatment of “OFF” Episodes in Patients with Parkinson’s Disease: Clinical and Exposure Response Findings

    F. Stocchi, C. Olanow, E. Peckham, F. Agbo, Y. Chiu, K. Sciarappa, B. Navia (Rome, Italy)

    Objective: Evaluate if dose optimization (DO) of apomorphine sublingual film (APL-130277; APL) can achieve improved FULL “ON” response in patients with Parkinson’s disease (PD) and…
  • MDS Virtual Congress 2020

    A Discrete-Choice Experiment Evaluating Preferences for On-Demand Treatments for Patients with Parkinson’s Disease and “OFF” Episodes

    A. Thach, J. Sutphin, J. Coulter, C. Mansfield (Marlborough, MA, USA)

    Objective: To quantify patient preferences for on-demand treatments among patients with Parkinson’s disease (PD) and “OFF” episodes. Background: Patients with PD develop potentially disabling “OFF”…
  • MDS Virtual Congress 2020

    Budget Impact of Apomorphine Sublingual Film for On-Demand Treatment of Patients With Parkinson’s Disease and “OFF” Episodes

    A. Thach, N. Kirson, M. Zichlin, I. Dieye, E. Pappert, G. Williams (Marlborough, MA, USA)

    Objective: To estimate the budget impact of introducing apomorphine sublingual film (APL-130277; APL) as an on-demand treatment for patients with Parkinson’s disease (PD) and “OFF”…
  • MDS Virtual Congress 2020

    On-Demand Treatment Preferences of Patients with Parkinson’s Disease and “OFF” Episodes: Heterogeneity Across Patient Subgroups

    A. Thach, J. Coulter, C. Leach, J. Sutphin, C. Mansfield (Marlborough, MA, USA)

    Objective: To quantify preference heterogeneity for on-demand treatments among patients with Parkinson’s disease (PD) and “OFF” episodes. Background: Patients with PD commonly experience “OFF” episodes.…
  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • …
  • 12
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • The hardest symptoms that bother patients with Parkinson's disease
  • The clinical effects of mucuna and green tea in combination with levodopa-benserazide in advanced Parkinson's disease: Experience from a case report
  • To be or not to bupropion: a drug-induced parkinsonism?
  • #25822 (not found)
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Restless Leg Syndrome After Propranolol Intake: A Single Case
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley